135.83
price up icon2.26%   3.00
after-market After Hours: 135.83
loading
Ligand Pharmaceuticals Inc stock is traded at $135.83, with a volume of 124.87K. It is up +2.26% in the last 24 hours and up +17.38% over the past month. Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$132.83
Open:
$133.62
24h Volume:
124.87K
Relative Volume:
0.89
Market Cap:
$2.62B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
54.12
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
-2.35%
1M Performance:
+17.38%
6M Performance:
+18.08%
1Y Performance:
+28.13%
1-Day Range:
Value
$132.59
$135.83
1-Week Range:
Value
$131.75
$143.13
52-Week Range:
Value
$90.29
$143.13

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Name
Name
Ligand Pharmaceuticals Inc
Name
Phone
858-550-7500
Name
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Name
Employee
68
Name
Twitter
@Ligand_LGND
Name
Next Earnings Date
2025-02-18
Name
Latest SEC Filings
Name
LGND's Discussions on Twitter

Compare LGND with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LGND
Ligand Pharmaceuticals Inc
135.83 2.56B 152.42M 45.24M 6.97M 2.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-10-25 Initiated Stifel Buy
Oct-03-24 Initiated Oppenheimer Outperform
Jul-30-24 Initiated RBC Capital Mkts Outperform
Apr-14-21 Resumed Stephens Overweight
Feb-04-21 Reiterated H.C. Wainwright Buy
Oct-06-20 Initiated Barclays Overweight
Mar-24-20 Downgrade Argus Buy → Hold
Mar-10-20 Initiated Guggenheim Neutral
Feb-06-20 Initiated The Benchmark Company Buy
Sep-19-19 Upgrade Barclays Equal Weight → Overweight
Jun-11-19 Initiated Barclays Equal Weight
May-03-19 Reiterated H.C. Wainwright Buy
Mar-06-19 Reiterated H.C. Wainwright Buy
Oct-29-18 Upgrade ROTH Capital Neutral → Buy
Oct-02-18 Reiterated H.C. Wainwright Buy
Sep-11-18 Reiterated Argus Buy
Aug-17-18 Initiated Goldman Neutral
Aug-08-18 Downgrade ROTH Capital Buy → Neutral
Jun-21-18 Initiated Argus Buy
Dec-27-17 Reiterated H.C. Wainwright Buy
Sep-05-17 Resumed H.C. Wainwright Buy
Oct-05-16 Reiterated H.C. Wainwright Buy
Aug-05-16 Downgrade Deutsche Bank Hold → Sell
Mar-11-16 Initiated Sidoti Buy
Mar-03-16 Initiated H.C. Wainwright Buy
View All

Ligand Pharmaceuticals Inc Stock (LGND) Latest News

pulisher
04:50 AM

Is Ligand Pharmaceuticals Incorporated stock a growth or value playInvestor Friendly Risk Reward - Metal.it

04:50 AM
pulisher
Jul 25, 2025

Ligand Pharmaceuticals Incorporated Stock Analysis and ForecastHigh-margin investment plays - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Ligand Pharmaceuticals Incorporated stock priceBreakout portfolio performance - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Mark Your Calendar: Ligand Q2 2025 Earnings Report Coming August 7Key Details Inside - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Ligand Pharmaceuticals Incorporated stockExceptional trading performance - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Ligand Pharmaceuticals Incorporated a good long term investmentHigh-velocity capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Sarepta Therapeutics (SRPT) - The Globe and Mail

Jul 18, 2025
pulisher
Jul 17, 2025

Stifel reiterates Buy rating on Ligand Pharma stock at $143 price target - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD - Investing.com Australia

Jul 16, 2025
pulisher
Jul 16, 2025

Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD By Investing.com - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Ligand Pharmaceuticals Incorporated stock price move sharplyHigh Yield Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Ligand Pharmaceuticals Incorporated stock performs during market volatilityFree Real-Time Trading Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionFree Access to Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $140 - 富途牛牛

Jul 15, 2025
pulisher
Jul 14, 2025

Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand Pharmaceuticals director Kozarich sells $116k in stock By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand Pharmaceuticals director Kozarich sells $116k in stock - Investing.com Australia

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand Pharmaceuticals Director John Kozarich Sells 934 Shares at $125/Share. - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Amalgamated Bank Has $564,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand earns $5 million milestone as partner launches molluscum treatment By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 10, 2025

Ligand Pharmaceuticals (LGND) Soars 2.11% on ZELSUVMI Launch, Milestone Payment - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Pelthos Therapeutics shares rise 1.27% in after-hours after commercial launch of ZELSUVMI™ and merger with Channel Therapeutics. - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts - Stocktwits

Jul 10, 2025
pulisher
Jul 10, 2025

ZELSUVMI's FDA Approval: A Breakthrough for Pelthos and a Windfall for Ligand? - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

ZELSUVMI Launch Positions Ligand Pharmaceuticals for Growth in a Booming Skin Care Market - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand earns $5 million milestone as partner launches molluscum treatment - Investing.com

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Pharmaceuticals Partner Pelthos Launches Molluscum Contagiosum Treatment Zelsuvmi - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand (LGND) Advances with Successful Launch of ZELSUVMI Gel | - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ZELSUVMI™ for Molluscum Contagiosum Treatment - Quiver Quantitative

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ - GlobeNewswire

Jul 10, 2025
pulisher
Jul 10, 2025

Breakthrough: First-Ever At-Home Treatment for Molluscum LaunchesLigand Secures $5M Milestone Payment - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

GAMMA Investing LLC Has $62,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 09, 2025
pulisher
Jul 05, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of “Buy” from Analysts - Defense World

Jul 05, 2025
pulisher
Jul 03, 2025

Ligand’s LNHC concludes merger with CHRO - Yahoo Finance

Jul 03, 2025
pulisher
Jul 02, 2025

Ligand Pharma Completes Merger Forming Pelthos Therapeutics - TipRanks

Jul 02, 2025
pulisher
Jul 02, 2025

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - The Manila Times

Jul 02, 2025

Ligand Pharmaceuticals Inc Stock (LGND) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):